Drug Profile
A 400
Alternative Names: A-400Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator AfaSci
- Class Antiepileptic drugs; Sleep disorder therapies
- Mechanism of Action Ion channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Epilepsy; Insomnia
Highest Development Phases
- No development reported Epilepsy; Insomnia
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Epilepsy in USA
- 28 Aug 2020 No recent reports of development identified for research development in Insomnia in USA
- 22 Jul 2016 A 400 is available for licensing as of 22 Jul 2016. http://www.afasci.com/index.php/